Use of Adjuvant Intralesional Bevacizumab for Aggressive Respiratory Papillomatosis in Children | Head and Neck Cancer | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Original Article
May 2013

Use of Adjuvant Intralesional Bevacizumab for Aggressive Respiratory Papillomatosis in Children

Author Affiliations

Author Affiliations: Departments of Pediatric Otolaryngology (Drs Rogers and Hartnick) and Otolaryngology–Head and Neck Surgery (Dr Ojha), Massachusetts Eye and Ear Infirmary, Boston; and Brigham and Women's Hospital and Massachusetts General Hospital, Boston (Ms Maurer).

JAMA Otolaryngol Head Neck Surg. 2013;139(5):496-501. doi:10.1001/jamaoto.2013.1810

Importance Juvenile recurrent respiratory papillomatosis (RRP) can be an aggressive disease process necessitating frequent trips to the operating room with multiple anesthetics for tumor debulking and airway preservation. Adjuvant therapy, such as that which is reported in this article, may help reduce the number of operative procedures affected children need each year and therefore may also affect their overall quality of life (QOL).

Objective To describe our experience with intralesional bevacizumab (Avastin) treatment for children with severe RRP by comparing median number of surgical procedures per year, median duration of time between procedures, Derkay staging, and voice QOL before and after bevacizumab treatment.

Design Prospective, consecutive case series.

Setting Tertiary care aerodigestive center.

Participants Ten children, aged 18 months to 18 years, with severe RRP necessitating more than 4 operative interventions in 1 year whose parents (or legal guardians) consented to intralesional bevacizumab treatment.

Interventions Intralesional bevacizumab administered at concentration of 2.5 mg/mL for 3 consecutive injections (with 532-nm pulsed KTP [potassium titanyl phosphate] laser when necessary) at intervals of 2 to 3 weeks.

Main Outcome Measures Time between surgical procedures, number of procedures per year, Derkay staging, total Pediatric Voice-Related Quality of Life (PVRQOL) score, Emotional PVRQOL score, and Physical PVRQOL score defined by comparing the year leading up to first of 3 bevacizumab injections with the year following the third bevacizumab injection.

Results The median duration of time between surgical procedures increased by 5.9 weeks after bevacizumab (P = .002). The median number of procedures per year decreased by 4 (P = .002). Derkay staging decreased by 6 (P = .03). The median total PVRQOL score increased by 25.5 (P = .02), the median Emotional PVRQOL score increased by 11.3 (P = .047), and the median Physical PVRQOL score increased by 14.3 (P = .047).

Conclusions and Relevance Intralesional bevacizumab treatment may increase duration of time between surgical procedures and decrease number of procedures per year, while improving voice QOL.